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Eclipta alba, an indigenous medicinalplant, has a folk (Siddha andAyurvedha) reputation in
ruralsouthem India as a hypoglycemic agent. In orderto confirm this claim, thepresentstudy
was carried out to evaluate the antihyperglycemic effect ofE. alba and to study the activities
ofliverhexokinase andgluconeogenic enzymessuch asglucose-6-phosphatase andfructose
1,6-bisphosphatase in the liverofcontrolandalloxan-diabetic rats. Oraladministration ofleaf
suspension ofE. alba (2 and4 g/kg body weight) for60 days resultedinsignificant reduction
in blood glucose (from 372.0 ± 33.2 to 117.0 ± 22.8), glycosylated hemoglobin HbA1c, a
decrease in the activities ofglucose-6phosphatase andfructose1,6-bisphosphatase, andan
increase in the activityofliverhexokinase. E. alba atdose of2g/kgbodyweightexhibitedbet-
ter sugar reduction than 4 g/kg body weight. Thus, the present studyclearly shows that the
oral administration ofE. alba possess potentantihyperglycemic activity.
INTRODUCTION
Diabetes mellitus is the most common
disease associated with carbohydrate
metabolism, affecting about 200 million
people worldwide. Extracts of various
plant materials capable of decreasing
blood sugar have been tested in experi-
mental animal models and their effects
confirmed [1]. Many unknown and lesser-
known plants are used in folk and tribal
medicinal practices in India. The medici-
nal values of these plants are not much
known to the scientific world. E. alba
(Family Compositae) is one such medici-
nal plant popularly used for the inflamma-
tion, anthelmintic, astringent, deobstruent
[2], and hepatoprotective effect [3]. E.
alba is one of the ingredients of Trasina,
the largest selling Ayurvedic antihyper-
glycemic drug (Dey's Medical, Calcutta)
in India. [4]. It has been reported in a son-
net [5] thatE. alba along with black cumin
seeds (Nigella sativa L.) is capable of
reducing sugar. Saint Ramalinga (Vallalar)
in his songs advocates the intake of E.
alba daily to strengthen body vitality [6].
Preliminary study in our laboratory is
highly encouraging and revealed that sig-
nificant blood glucose reduction was
observed in alloxan-diabetic rats. This
effect has never been experimentally
demonstrated. Thus, we considered it
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interesting to check whether there is any
scientific basis for the wide use in South
India ofE. alba as a hypoglycemic agent.
MATERIALS AND METHODS
Plant material
Eclipta alba L. Hassk. (syn. E. pros-
trata L., Asteraceae) popularly known as
"Karichalankanni" in Tamil, "Bhangra" in
English, and "Bringaraja" in Sanskrit, is an
erect or prostrate, much branched plant,
with white flower heads and is found in
almost all parts of India, particularly in
cool and moist places. E. Alba was col-
lected in the area of Vallampadugai vil-
lage, South Arcot district, Tamilnadu,
India, in November. The herbarium ofthis
plant was identified and authenticated
[Herbarium No. 906460] by Botanical
Survey of India, Coimbatore, Tamilnadu,
India.
Preparation ofplant material
Fresh leaves were collected and air-
dried in shade at room temperature. The
dried leaves were powdered mechanically
and sieved using a fine muslin cloth. The
fine powdered leaves were kept separately
in airtight containers in a room tempera-
ture until the time of use. Two-percent
gum acacia is used as vehicle solution.
Experimental animals
Male albino Wistar rats (150 to 200 g)
bred in the Central Animal House, Rajah
Muthiah Medical College, Annamalai
University, were used in this study. The
animals were fed on a pellet diet
(Hindustan Lever, India) and wateradlibi-
tum. The animals were maintained in their
respective groups for 60 days. All studies
were conducted in accordance with the
National Institute ofHealth's Guideforthe
Care and Use ofLaboratory Animals [7],
and the study was approved by the
Institutional Ethical Committee of Rajah
Muthih Medical College and Hospital,
Annamalai University, Annamalai Nagar,
Tamilnadu, India.
Experimental induction ofdiabetes
Diabetes was induced in male Wistar
albino rats by intraperitoneal administra-
tion of alloxan monohydrate (150 mg/kg
body weight) dissolved in normal saline.
Since alloxan is capable ofproducing fatal
hypoglycemia as a result of massive pan-
creatic insulin release, rats were treated
with 30 percent glucose solution orally at
different time intervals after six hours of
alloxan induction, and 5 percent glucose
solution was kept in bottles in their cages
for the next 24 hr to prevent hypo-
glycemia. After 10 days, rats with diabetes
mellitus having glycosuria (indicated by
Benedict's test) and hyperglycemia with
blood glucose range of 250 to 375 mg/dl
were used for this experiment.
Experimental design
Animals were divided into six groups
of six rats each. Feed and water were pro-
vided ad libitum to the animals:
* Group 1, Control vehicle
only (2 percent gum acacia).
* Group 2, Diabetic control.
* Group 3, Control + E. Alba
suspension (2 g/lkg body wt).
* Group 4, Diabetic + E. Alba
suspension (2 g/kg body wt).
* Group 5, Diabetic + E. Alba
suspension (4 g/lkg body wt.).
* Group 6, Diabetic +
glibenclamide (600 mg/kg
body wt).
The leafsuspension was given by oral
intragastric tube. After 60 days of treat-
ment, the rats were fasted overnight and
sacrificed by cervical decapitation. The
blood glucose [8] and glycosylated hemo-
globin [9] were estimated. The liver was
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saline immediately. Aportion of the tissue
was homogenized using a Potter-Elvejham
homogenizer, and the extract was used for
the estimations of hexokinase [10], glu-
cose 6-phosphatase [11], fructose 1,6-bis-
phosphatase [12], protein [13], hemoglo-
bin [14], inorganic phosphorus [15], and
blood urea [16] using a semi-autoanalyzer.
Statistical analysis
Values were represented as mean +
SD. Data were analyzed using analysis of
variance and group means were compared
with Duncan's multiple range test.
RESULTS
Changes in blood glucose and body
weight in diabetic and on treatment ofdia-
betic rats with E. Alba, glibenclamide are
presented in Table 1. Asignificant increase
in blood glucose and significant reduction
in body weight are observed in diabetic
rats when compared with control rats. Oral
administration of E. Alba (2 and 4 g/kg
body weight) for60days shows significant
reduction in blood glucose and a remark-
able improvement in body weight in dia-
betic rats when compared with untreated
diabetic rats. Table 2 shows the effects of
E. Alba and glibenclamide on hemoglobin,
glycosylated hemoglobin, serum protein,
and urea in control and alloxan-diabetic
rats. There is a significant reduction in
hemoglobin and serum protein while gly-
cosylated hemoglobin and blood urea sig-
nificantly increased in diabetic rats when
compared with control rats. Oral adminis-
tration of E. Alba (2 and 4 g/kg body
weight) significantly brings the value to
near normal. Effects on the administration
of E. Alba and glibenclamide on hepatic
hexokinase and glucose-6-phosphatase,
fructose-1, 6-bisphosphatase of liver are
presented in Table 3. The activity ofhepat-
ic hexokinase is significantly decreased
while glucose-6-phosphatase and fructose-
1, 6-bisphosphatase are significantly ele-
vated in allaxon treated diabetic rats as
compared to normal rats. Administration
of E. Alba (2 and 4 g/kg body wt) and
glibenclamide increases the activity of
hexokinase and decrease the activities of
glucose 6-phosphatase and fructose-1,6-
Table 1. Changes in blood glucose and body weight in control and alloxan diabetic
rats treated with E. alba and glibenclamide.
Blood glucose Body weight
(mg/dl) (g) Changes
body wt.
Groups Initial Final Initial Final (g)
Control 81 ± 5.6 85.6 + 4.8a 170 + 5.8 211 + 8.7 +41
(2% gum acacia)
Diabetic control 353 + 18.5 393 + 13.6b 195 + 4.1 125 ± 4.1 -70
Control + E. alba 89.3 + 6.8 90.2 + 5.4a,c 166 + 11.8 172.6 + 12.4 +6.6
(2 g/kg body wt)
Diabetic + E. alba 372 + 33.1 117 ± 22.8d 193 + 4.7 166 +16.9 -27
(2 g/kg body wt)
Diabetic + E. alba 364 + 36 159 + 38Cd 182 + 17.5 147 + 17.5 -35
(4 g/kg body wt)
Diabetic + glibenclamide 267 + 29 187 + 12.5a,d 182 + 17.5 147 + 17.5 -35
(600 pg/kg body wt)
Values are mean + SD for six animals each. Values not sharing a common superscript differ signifi-
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Table 2. Effect of E. alba on hemoglobin, glycolylated hemoglobin (HbA1c), protein,
and urea in control and alloxan diabetic rats.
Glycolylated
Hemoglobin hemoglobin Protein Urea
Groups (g%) (mg/g of Hb) (gIdl) (mg/dl)
Control 14.05 + 0.9 0.203 + 0.04a 5.82 + 0.18a 22.0 + 2.0a
(2% gum acacia)
Diabetic control 9.06 + 1.7 0.569 + 0.08b 4.20 + 0.37b 38.6 + 6.8b
Control + E. alba 14.4 + 0.4 0.205 + 0.03a 5.83 + 0.27a 22.0 + 2.0a
(2 g/kg body wt)
Diabetic + E. alba 13.53 + 1.5 0.286 + 0.02c 5.06 + 0.08c 24 + 3.3a,d
(2 g/kg body wt)
Diabetic + E. alba 14.6 + .7 0.268 + 0.05a,c 5.42 + 0.64ac 33.0 + 6.0d
(4 g/kg body wt)
Diabetic + glibenclamide 12.23 + 0.6 0.239 + 0.02a,c 5.43 + 0.44a,C 22.0 + 2.0a
(600 pg/kg body wt)
Values are mean + SD for six animals each. Values not sharing a common superscript differ signifi-
cantly at p < .05. DMRT, Duncan's multiple range test.
bisphosphatase as compared to diabetic
rats. Control animals administered with E.
Alba 2 g/kg body weight do not show any
significant changes in the any of the para-
meters studied.
DISCUSSION
Blood sugarlevel increased as expect-
ed in alloxan-injected animals, since allox-
an causes a massive reduction in insulin
release, by the destruction ofthe beta-cells
of the islets of Langerhans and inducing
hyperglycemia [17]. Oral administration
of E. Alba (2 and 4 g/kg body wt.) result-
ed in a significant reduction in the blood
glucose and improvement in body weight.
The decrease in body weight in diabetic
rats clearly shows a loss or degradation of
structural proteins due to diabetes. The
structural proteins are known to contribute
for the body weight [18]. Protein synthesis
is decreased in all tissues due to absolute
or relative deficiency of insulin (an ana-
bolic hormone) in alloxan-induced diabet-
ic rats. The ability ofthe E. Alba to protect
from maximum body weight loss seems to
be due to its ability to reduce hyper-
glycemia. The present study also indicates
that
E. Alba can inhibit alloxan renal toxi-
city as seen from the blood urea level. The
glycosylated hemoglobin gives an idea
aboutpatient's overall glucose levels in the
preceding six to eight weeks. Glycosylated
hemoglobin comprises about 3.4 to 5.8
percent total hemoglobin in normal human
red cells, but it is increased in patients of
overt diabetes [19]. It is found to increase
in diabetic patients up to 16 percent and
the amount ofthis increase is directly pro-
portional to the long lasting fasting blood
sugar level. In our study, the glycosylated
hemoglobin level was high showing that
the diabetic animals had high blood glu-
cose level. The values decreased very
much in E. Alba-administered animals
showing the influence of the leaf suspen-
sion on sugar reduction.
Insulin influences theintracellular uti-
lization of glucose in a number of ways.
Insulin increases hepatic glycolysis by
increasing the activity and amount of sev-
eral key enzymes including glucokinase,
phosphofructokinase, and pyruvate kinase.
Hexokinase is universally present in cellsAnanthi et al.: Eclipta alba and hyperglycemia 101
Table 3. Effect of E. alba on the activities of hepatic enzymes in control and
experimental animals.
Glucose-6- Fructose 1,6-
Glucokinase phosphatese biphosphatese
Groups (Unita/mg protein) (Unitb/mg protein) (Unitc/mg protein)
Control 0.241 +0.035a 0.186 +0.005a 0.419 + 0.020a
(2% gum acacia)
Diabetic control 0.082 +.005b 0.412 + 0.021b 0.681 + 0.075b
Control + E. a/ba 0.240 + 0.015a 0.180 + 0.030a 0.422 + 0.022a
(2 g/kg body wt)
Diabetic + E. alba 0.234 + 0.016a 0.287 + 0.007C 0.480 + 0.008c
(2 g/kg body wt)
Diabetic + E. alba 0.215 + 0.043a 0.255 + 0.036a,c 0.490 + 0.020c
(4 g/kg body wt)
Diabetic + glibenclamide 0.238 + 0.053a 0.223 + 0.026a,c 0.469 + 0.023a,c
(600 rig/kg body wt)
Values are mean + SD for six animals each. Values not sharing a common superscript differ signifi-
cantly at p < 0.05. DMRT, Duncan's multiple range test. a, pmoles of glucose phosphorylated/h; b,
pmoles of pi liberated/min; c, ,umoles of pi liberated/min.
of all types. Hepatocytes also contain a
form ofhexokinase calledhexokinase D or
glucokinase, which is more specific for
glucose and differ from other forms of
hexokinase in kinetic and regulatory prop-
erties [20]. Glucokinase (also hexokinase
IV) catalyzes the conversion ofglucose to
glucose-6-phosphate and play a central
role in the maintenance of glucose home-
ostasis.
In the liver, the enzyme is an impor-
tant regulator of glucose storage and dis-
posal [21]. In our study, the hexokinase
activity was decreased in alloxan-diabetic
rats which may be due to insulin deficien-
cy (insulin stimulates and activates glu-
cokinase). Treatment with E. Alba or
glibenclamide, elevated the activity ofglu-
cokinase in liver. E. Alba, like gliben-
clamide, may stimulate insulin secretion,
which may activate glucokinase, thereby
increasing utilization of glucose and thus
increased utilization leads to decreased
blood sugar level.
Insulin decreases gluconeogenesis by
decreasing the activities of key enzymes
such as glucose-6-phosphatase, fructose
1,6, bisphosphatase, phosphoenolpyruvate
carboxykinase, and pyruvate carboxylase
[22]. In our study, increased activities of
glucose-6-phosphatase and fructose-1,6
bisphosphatase were observed in the liver
of alloxan-diabetic rats. Glucose 6-phos-
phatase, one of the key enzymes in the
homeostatic regulation of blood glucose
level, catalyzes the terminal step in both
gluconeogenesis and glycogenolysis [23,
24] and fructose 1,6-bisphosphatase, cat-
alyzes one of the irreversible step in glu-
coneogeneis, and serves as a site for the
regulation ofprocess [25]. Increased activ-
ities of these two gluconeogenic enzymes
(glucose-6-phosphatase and fructose 1,6
bisphosphatase) in the liver may be due to
activation or increased synthesis of the
enzymes contributing to the elevated glu-
cose production in diabetes. Animals treat-
ed with E. Alba may primarily be modu-
lating and regulating the activities ofthese
two gluconeogenic enzymes either
through regulation of cAMP or inhibition
ofgluconeogenesis [26].
In conclusion, we have demonstrated
that the folk medicinal plant E. Alba pos-
sesses a hypoglycemic effect. Further,
active research is underway in our labora-102 Ananthi et al.: Eclipta alba and hyperglycemia
tory to elucidate the mechanisms ofaction
ofthis medicinally important plant.
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